We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mass Spectrometry Identifies Bacterial and Yeast Isolates

By LabMedica International staff writers
Posted on 24 Jan 2013
Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) is an automated molecular platform that can be used to identify pathogens. More...


The MALDI-TOF technique effectively circumvents many of the drawbacks of other methods and offers a rapid, straightforward, and inexpensive method to distinguish bacteria and yeasts isolates from human samples.

Scientists at the Mayo Clinic’s Department of Laboratory Medicine and Pathology (Rochester, MN, USA) have recently validated the use of MALDI-TOF in the clinical laboratory. Currently, they only perform MALDI-TOF MS analysis from isolated bacterial and yeast colonies, therefore clinical specimens continue to be plated to solid media and are observed for growth. They use the process referred to as the formic acid-based, direct on-plate preparation method and depending on room humidity, has a total preparation time of 10 to 20 minutes for 24 samples.

The Bruker Biotyper MALDI-TOF MS (Fällanden, Switzerland) system is used for routine identification of bacterial and yeast isolates from culture. The Bruker Biotyper system includes the Microflex LT/SH MS instrument and two software programs: FlexControl for acquisition of protein spectra and Biotyper real-time classification (RTC) for automated spectral analysis.

The team has evaluated 900 bacterial and yeast isolates, with an overall correct identification rate of 94.2% to the genus and 79.2% to the species levels. While genus level identification was above 90% for most of the evaluated organism groups, the lower species level identification percentage was primarily driven by the gram-positive cocci (69.5%). Some closely related bacterial species cannot be differentiated by MALDI-TOF MS, regardless of the system manufacturer. This technology cannot reliably distinguish Escherichia coli from Shigella species or Streptococcus pneumoniae from S. mitis group species.

Identification of unknown isolates by this technology is based on the acquisition of unique protein profiles from isolated colonies and comparison of this data to a library of reference spectra derived from well-characterized isolates. The Mayo scientists have shown that has shown that MALDI-TOF MS is a rapid and inexpensive method able to accurately identify isolates within minutes, compared to the more time-consuming methods associated with other automated microbial identification systems and the potentially subjective nature of classic biochemical analyses.

Related Links:

Mayo Clinic
Bruker



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.